SUMMARY Gabapentin, -(aminomethyl) cyclohexane acetic acid, is a GABA analogue whose antiepileptic properties were tested in a double blind cross-over trial design as add-on therapy in a dose ranging study which compared 300 mg, 600 mg, and 900 mg/day (each dose given for 2 months) in 25 patients with severe partial and generalised epilepsies. A dose related antiepileptic effect was observed. All We report the first study of the antiepileptic properties of gabapentin in 25 patients with severe epilepsies resistant to standard antiepileptic drugs. The effects of three different doses of the drug have been compared in a double blind crossover trial design.
Gabapentin, l-(aminomethyl) cyclohexane acetic acid (fig 1) , is a GABA analogue that is well absorbed and penetrates the blood brain barrier. It is effective against a variety of seizures in animals particularly those caused by interference with GABAergic transmission or provoked by excitatory amino acids.' In spite of this the precise mechanism of its antiepileptic properties is unclear as gabapentin does not appear to alter whole brain levels of GABA or have significant effects on GABA transaminase activity. It does not show any significant binding to GABA or benzodiazepine receptors and does not influence neuronal uptake of GABA at pharmacologically relevant doses. ' We report the first study of the antiepileptic properties of gabapentin in 25 patients with severe epilepsies resistant to standard antiepileptic drugs. The effects of three different doses of the drug have been compared in a double blind crossover trial design.
Methods
The trial design was that of a three way double blind crossover study. All patients were followed for an initial two month baseline period during which they received one or two standard antiepileptic drugs. Seizure frequency and adverse effects were documented. All patients then received a two week titration phase in which 300 mg and 600 mg of gabapentin was given. At zures, one patient had complex absences associated with tonic-clonic seizures. Probable aetiological factors were identified in 15 patients. Perinatal insults had occurred in six patients, the epilepsy was post-encephalitic in three and post traumatic in two. One patient developed epilepsy after a prolonged febrile convulsion, and three patients had non-progressive structural lesions on CT scanning (two low density, one calcification). Neurological signs were present in two patients, one of whom was blind because of choroido-retinitis and one of whom had a mild left hemiparesis. Seven patients had an IQ of 80 or less.
Three patients were taking one standard antiepileptic drug and 22 were receiving two drugs (in three of these benzodiazepines were also prescribed). Carbamazepine was administered to 21 patients, valproate to 13, phenytoin to 11, primidone to one, and phenobarbitone to one. Doses of these drugs were such as to maintain adequate serum concentrations.
Results

Efficacy
Four patients were excluded from the analysis of efficacy. One patient developed absence status during the two week titration phase. Similar episodes occurred frequently in this patient and had occurred when he had previously been challenged with new anticonvulsant drugs. He did not enter the formal part of the study. Two patients were excluded from analysis because of questionable compliance and poor documentation of their seizures during the course of the study. One patient had phenobarbitone added to his therapy by the general practitioner during the course of the study.
All subsequent data on efficacy were derived from 21 patients. Three patients terminated the third treatment phase prematurely four weeks before it was due to end. All three patients showed evidence of reduced efficacy in the third period compared to previous periods. Two of these patients were receiving 300 mg/day gabapentin in the third period and the third patient 900 mg/day. Data from these patients has been in-683 (1) (1)
12-0 (1) and 11 am, two to three hours after the initial dose of anticonvulsants.
Serum concentrations of standard antiepileptic drugs are presented in table 4 during baseline and during the three treatment periods. There was no change in any baseline blood levels although there was a trend towards elevation of serum phenytoin concentration in patients taking 900 mg/day of gabapentin.
Detailed plasma concentration assays for gabapentin were undertaken in five patients during 24 hour periods when they were receiving 900 mg per day (one patient), 600mg per day (three patients), and 300mg per day (one patient) (fig 3a) . It can be seen that blood levels at 11 am., two hours after the initial dose of gabapentin, are approximately twice the trough levels, but the peak levels during the 24 hours were attained at approximately 1700 hrs (three hours after the midday dose). Similar 24 hour monitoring in each of these five patients was repeated two weeks later. Repeat testing did not show any evidence of auto-induction.
Mean concentrations of gabapentin for each patient at the three doses of gabapentin that they received are presented in fig 3b. It can be seen that there is a satisfactory linear relationship between dose and serum concentration in all cases where serum sampling time was similar (19 patients).
Discussion
Over recent years there has been an increased understanding of the role of the inhibitory neurotransmitter, GABA, in the control of seizure threshold. This has achieved direct clinical relevance with clinical testing of y-vinyl GABA, a GABA transaminase inhibitor,8 and progabide, a GABA prodrug and GABA agonist,9 as potential antiepileptic drugs. Gabapentin was synthesised as a GABA analogue and whilst it appears to possess GABA mimetic properties its precise mode of action remains uncertain.
This first study was designed to compare the relative efficacy of three different doses of gabapentin in patients with severe partial and generalised epilepsies. The results indicate that 900mg/day of gabapentin has greater antiepileptic properties than 300mg and 600mg/day against all seizure types considered together. There is evidence of a dose related antiepileptic effect that is statistically significant when all seizures are considered together and similar trends are seen when partial seizures, and tonic-clonic seizures are considered separately. The median frequency of tonic-clonic seizures was reduced most dramatically.
Gabapentin as an antiepileptic drug in man 685 a group.bmj.com on May 1, 2017 -Published by http://jnnp.bmj.com/ Downloaded from Whilst the direct dose to dose comparisons infer antiepileptic efficacy they cannot be regarded as providing definite proof. Whilst the median frequency of all seizures was reduced by 30% compared with baseline frequency (50% reduction for partial seizures, and 70% reduction for tonic-clonic seizures) these results must be interpreted with caution. There was no random allocation between baseline period and a drug dosage, and placebo was not given during the baseline period. Whilst it seems highly unlikely that the results can be explained by a placebo effect, this present trial design cannot definitely exclude such a possibility.
The study relates only to a relatively short period of treatment. However, some 15 patients have continued gabapentin therapy for periods now approaching 12 months. So far there is no evidence of the development of tolerance in the antiepileptic effects of gabapentin in our patients.
It is of some interest to compare the results of this study with those of another study recently performed in this department. This was also a three-way crossover study comparing the addition of progabide, valproate and placebo as add-on therapies.9 Whilst the trial designs differ in that in the latter study treatment periods were for 6 months, and there was random allocation between placebo and the two active drugs, the majority of patients taking part in the gabapentin study also took part in the previous study. We cannot draw firm conclusions but the results obtained with gabapentin appear quantitatively very similar to those obtained with valproate and the spectrum of activity of valproate and gabapentin appear similar, both being moderately effective against partial seizures and highly effective against tonic-clonic seizures. This study has shown little evidence of adverse effects and detailed psychometric testing failed to show any significant changes. Importantly, there was no evidence that gabapentin has significant interactions with other antipileptic drugs. This may have been expected as the drug is largely excreted unmetabolised, and does not undergo significant protein binding.
Gabapentin thus appears to be a promising antiCrawford, Ghadiali, Lane, Blumhardt, Chadwick epileptic drug. The next necessary step will be a direct proof-of-efficacy study comparing gabapentin with placebo in a double-blind fashion as add on therapy. If further study confirms the present impressions of an effective antiepileptic drug relatively free of side effects and drug interaction, there is every possibility that gabapentin may prove a significant addition to the range of drugs available for the treatment of human epilepsy.
